<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538342</url>
  </required_header>
  <id_info>
    <org_study_id>11-API-03</org_study_id>
    <nct_id>NCT01538342</nct_id>
  </id_info>
  <brief_title>Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis</brief_title>
  <official_title>Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory
      caspases, cysteine proteases involved in the processing of many proteins, are activated.
      Transgenic mice expressing the cleaved form of caspases by Lyn, a tyrosine kinase Src family,
      develop an inflammatory syndrome with the characteristics of human psoriasis.

      To clarify the relationship between the cleaved form of Lyn by caspases and psoriasis, the
      investigators intend to develop a clinical study to analyze the expression, cleavage and
      activity of Lyn and the activation of caspases from skin biopsies of patients with this
      disease.

      This study will be conducted on a cohort of patients with different forms of psoriasis
      (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated
      with chronic inflammation. Thus, the investigators will evaluate the expression and activity
      of Lyn from skin lesion (L) and non-lesional (NL) from the same patient in parallel with the
      level of caspase activation and apoptotic inflammatory.

      Thus, the investigators will verify that the cleavage by caspases of Lyn is associated
      specifically with psoriasis, as the investigators believe, or more generally to the skin
      inflammation. The investigators work would then define the cleavage by caspases of Lyn as a
      new potential marker of human psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cleavage of Lyn</measure>
    <time_frame>1 day</time_frame>
    <description>The cleavage of Lyn will be determined in the different extracts of skin of patients with western blotting using an antibody specific for Lyn recognizing the native form but also the form cleaved by caspases.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expression levels of Lyn</measure>
    <time_frame>1 day</time_frame>
    <description>The expression levels of Lyn and its cleaved form will be quantified using the software MultiGauge. The investigators will also determine the level of activity of Lyn using an antibody directed against the active form phosphorylated. The level of expression of proteins of interest will be reported at the level of protein expression control (ERK2) whose expression does not vary depending on the samples (load control).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific activity of apoptotic caspases 3, 6, 7, 8 and 9, and inflammatory caspases 1, 4, and 5</measure>
    <time_frame>1 day</time_frame>
    <description>The investigators will determine the specific activity of apoptotic caspases 3, 6, 7, 8 and 9, and inflammatory caspases 1, 4, and 5 test microplate. The principle of this test is based on the use of a specific substrate of caspases coupled to a fluorochrome that fluoresces when it is released after the action of caspase-level target aspartate. The fluorescence emission, which is proportional to the amount of active caspase in the sample is then measured with a fluorometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of a monoclonal antibodyspecific for the cleaved form of caspases by Lyn</measure>
    <time_frame>1 day</time_frame>
    <description>Development of a monoclonal antibody specific for the form cleaved by caspases of Lyn. Once obtained and validated, this tool will be especially useful for immunohistological analysis of Lyn on skin sections from patients with psoriasis. Then we can also analyze which skin cells express preferentially cleaved form of Lyn.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Psoriasis</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>chronic plaque psoriasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 biopsies: 2 lesional and 1 non-lesional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pustular psoriasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 biopsies: 2 lesional and 1 non-lesional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>erythrodermic psoriasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 biopsies: 2 lesional and 1 non-lesional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atopic dermatitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 biopsies: 1 lesional and 1 non-lesional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 biopsy of healthy skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3 Biopsies</intervention_name>
    <description>3 biopsies: 2 lesional and 1 non-lesional</description>
    <arm_group_label>chronic plaque psoriasis</arm_group_label>
    <arm_group_label>pustular psoriasis</arm_group_label>
    <arm_group_label>erythrodermic psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 biopsies</intervention_name>
    <arm_group_label>atopic dermatitis</arm_group_label>
    <other_name>1 lesional and 1 non-lesional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>1 biopsy ok healthy skin</description>
    <arm_group_label>healthy patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Psoriasis arms:

          -  Plaque psoriasis and erythrodermic more than 10% of body surface area.

          -  Pustular psoriasis of at least 1% of body surface.

               -  Atopic dermatitis arm:Patients with atopic dermatitis has been identified and
                  inflammatory lesions on the skin.

               -  Healthy arm:People not suffering from any skin disease

        Exclusion Criteria:

          -  Systemic treatment of psoriasis for at least 4 weeks and / or local treatment for at
             least 2 weeks at the time of study entry.

          -  Patient with significant infection and / or immunocompromised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul ORTONNE, PU-PH</last_name>
    <role>Study Director</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandrine MARCHETTI, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Aleth RICHARD, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carle PAUL, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Paul ORTONNE, PU-PH</last_name>
    <phone>04 92 03 64 88</phone>
    <phone_ext>+33</phone_ext>
    <email>ortonne@unice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine MARCHETTI, PhD</last_name>
    <phone>04 93 37 70 16</phone>
    <phone_ext>+33</phone_ext>
    <email>Sandrine.Marchetti@unice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13 005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Aleth RICHARD, PU-PH</last_name>
      <phone>04 91 38 79 91</phone>
      <phone_ext>+33</phone_ext>
      <email>mrichard@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Aleth RICHARD, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carle PAUL, PU-PH</last_name>
      <phone>05 61 77 76 75</phone>
      <phone_ext>+33</phone_ext>
      <email>paul.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Carle PAUL, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2133.1999.140S54001.x/abstract</url>
    <description>Recent developments in the understanding of the pathogenesis of psoriasis</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>April 22, 2016</last_update_submitted>
  <last_update_submitted_qc>April 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

